Website
N/ATelephone
61.13.0097.4621
Address
324 Queen Street Brisbane, Queensland (QLD) 4000
Description
Microba Life Sciences Ltd. analyzes the microbiome to discover novel therapeutics and develop new diagnostic tools. Its therapeutic discovery platform,analysis platform and discovery platform uses human data and informatic approaches to connect microbial genotype to human phenotype. The firm offers microbiome testing services via distribution partners, and is working on microbial cell therapies for inflammatory bowel disease, cancer immunotherapy and autoimmune disease. The company was founded by Gene Tyson and Philip Hugenholtz in 2017 and is headquartered in Brisbane, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.2 - 0.42
Trade Value (12mth)
AU$24,064.00
1 week
-6.67%
1 month
-6.67%
YTD
-29.36%
1 year
-32.57%
All time high
0.424688
EPS 3 yr Growth
57.400%
EBITDA Margin
-342.90%
Operating Cashflow
-$12m
Free Cash Flow Return
-34.00%
ROIC
-34.80%
Interest Coverage
-307.60
Quick Ratio
5.20
Shares on Issue (Fully Dilluted)
365m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.37
Date | Announcements |
---|---|
31 October 23 |
Change of Director's Interest Notice - Pasquale Rombola
×
Change of Director's Interest Notice - Pasquale Rombola |
31 October 23 |
Change of Director's Interest Notice - Prof Ian Frazer
×
Change of Director's Interest Notice - Prof Ian Frazer |
31 October 23 |
Change of Director's Interest Notice - Richard Bund
×
Change of Director's Interest Notice - Richard Bund |
31 October 22 |
Investor Presentation Q1 FY23 Update
×
Investor Presentation Q1 FY23 Update |
31 January 23 |
Q2 FY23 Quarterly Investor Presentation
×
Q2 FY23 Quarterly Investor Presentation |
31 August 22 |
Therapeutic Program Advancement
×
Therapeutic Program Advancement |
30 October 23 |
Application for quotation of securities - MAP
×
Application for quotation of securities - MAP |
30 October 23 |
Letter to Shareholders, Notice of AGM & Proxy Form
×
Letter to Shareholders, Notice of AGM & Proxy Form |
30 October 23 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
30 November 23 |
2023 AGM Presentations
×
2023 AGM Presentations |
30 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 June 23 |
Notification of cessation of securities - MAP
×
Notification of cessation of securities - MAP |
30 June 22 |
Genova Diagnostics Partnership Commences in the US
×
Genova Diagnostics Partnership Commences in the US |
30 January 23 |
Details of Q2 FY23 Investor Webinar
×
Details of Q2 FY23 Investor Webinar |
30 January 23 |
Q2 FY23 Quarterly Activities Report & Appendix 4C
×
Q2 FY23 Quarterly Activities Report & Appendix 4C |
30 August 23 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 August 23 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
30 August 23 |
Appendix 4G
×
Appendix 4G |
30 August 22 |
Investor Presentation - FY22 Update Annual Results
×
Investor Presentation - FY22 Update Annual Results |
29 November 23 |
Change in substantial holding
×
Change in substantial holding |
29 November 22 |
Sonic Acquires 19.9% Microba Stake and Enters Partnership
×
Sonic Acquires 19.9% Microba Stake and Enters Partnership |
29 November 22 |
Sonic Investment & Partnership Investor Presentation
×
Sonic Investment & Partnership Investor Presentation |
29 November 22 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
29 November 22 |
Proposed issue of securities - MAP
×
Proposed issue of securities - MAP |
29 November 22 |
SHL: STRATEGIC STAKE AND COMMERCIAL PARTNERSHIP WITH MICROBA
×
SHL: STRATEGIC STAKE AND COMMERCIAL PARTNERSHIP WITH MICROBA |
29 May 23 |
Cleansing Notice
×
Cleansing Notice |
29 May 23 |
Application for quotation of securities - MAP
×
Application for quotation of securities - MAP |
29 March 23 |
Microba Receives Ethics Approval for Phase 1 Clinical Trial
×
Microba Receives Ethics Approval for Phase 1 Clinical Trial |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.